Capital eventCH· 2d ago
NeuroGyn AG closes CHF 4 million Series A to advance pelvic neuromodulation - Neurogyn
NeuroGyn AG raised CHF 4 million in a Series A led by a Swiss medical-technology investor, earmarked to fund initial human trials, regulatory advancement, and commercial development of its PosStim™ pelvic neuromodulation platform.
Intent
WARM· 56intent / 100
▸ why this score▾ score breakdown
- default: P(contract_to_capital_90d) · p=0.40 × w=3.0+1.2
- default: OON discount · × 0.75-0.5
- Final score (ambiguity-dampened) · default=56+56
- V2 winner: default · default=56+0
Go-to-market brief
NeuroGyn AG
companyCH
Daily 5 RWA signals
Five signals in your inbox each morning. Email only.
Free. The daily 5 lands at 07:00 UTC, nothing else. One-click unsubscribe in every email.